Osocimab - CISMeF

Preferred Label : Osocimab;

NCIt definition : A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against activated coagulation factor XI (FXIa), with potential anticoagulant and anti-thrombotic activities. Upon administration, osocimab targets, binds to, and allosterically inhibits FXIa. This prevents the activation of coagulation factor IX (FIX) by FXIa and the formation of thrombin. FXI plays an important role in thrombosis.;

UNII : EK5V9UL3WL;

CAS number : 2056878-75-0;

Molecule name : BAY-1213790; BAY 1213790;

NCI Metathesaurus CUI : CL1382755;

Codes from synonyms : 54147;

Details

Origin ID

C170268;

UMLS CUI

C5139912;

Automatic exact mappings (from CISMeF team)
- osocimab [MeSH concept]
Currated CISMeF NLP mapping
- osocimab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- osocimab [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients